London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I hope for the sakes of anyone who has sold on that petty 5% rise there’s no killer RNS in the morning otherwise you’ll be a prize plum.
Won’t be long before this is unleashed into the triple figures territory.
MB
No smoke without fire.
wait till you hear the confirmation.
If avct verification is end of this year, lots of time for odx to increase capacity.
"If they were going to increase capacity, why not increases capacity and make more of your own tests at higher margin!!!!"
I am sure the emphasis will be on the higher margin tests, but with this Gov't diversity is not a bad thing, so another large scale test would keep the bank manager, investors and staff happy, less risk the better all round.
Aberdeenman
If they were going to increase capacity, why not increases capacity and make more of your own tests at higher margin!!!!
Dropping the bid to 82p... RNS inbound?
Not sure about the excitement - it is more about the possibility of another test in the stable to manufacturer. Diversity in your manufacturing portfolio is a good thing. Mologic Antigen test is not ready yet and neither is Avacta's - both have major backing and different links (Mologic to Africa - Avacta to US). It is just good business and I think that is why people are excited, we are invested in a share that has many many strings to its bow and this is another. I dont quite understand what is not to like about it (if of course it is validated as true)
"Why would you use capacity on a product at low margin at the expense of making your own products at high margin?????
Unless Omega had infinite manufacturing capacity which is clearly not"
They won't, they have the expertise, so they will just increase capacity, likely takes a couple of months, which given the Avacta timelines, means they will be about to commit/ramp up.
That also means they will have to announce very very soon......
Aberdeenman
Point is , we will have an LFT to manufacture.
Doesn't matter who it comes from.
The fact that ODX aleady have an agreement with Mologic, and if the AVCT link is true, it means ODX will have capacity for both antigen LFTs as well as our antibody ones.
If need be, they will raise capacity from profit.
More is good.
ODX is about to pop.
Stay locked and loaded.
Question - what is Omega's margin on the Vivisect (Omega) branded mologic tests vs the margin they would get for manufacturing Avacta's test?? Why would you use capacity on a product at low margin at the expense of making your own products at high margin?????
Unless Omega had infinite manufacturing capacity which is clearly not the case, failed in their test developments, which they already have 2 out of 3 approved and track record suggests it will be 3.
BBI and Abingdon have nothing to lose as they have no other deals or entry into the antigen space.
At best Avacta tests are a hedge for investing in ODX as if ODX fails and Avacta get a test to market then of course capacity will be used.
I don't understand why people are getting excited about this, when we have a much better deal with Mologic already in place.
I would say that’s very close RNS update with Avacta. I would say today or tomorrow at the latest. Interesting that it’s not before year end so no faster than Mologic test which based on updates started quite a few weeks ahead. Maybe it’s getting clearer that these uk based businesses are working pretty well together and are looking to make for uk and then export massively for the benefit of all.
The three names are all RTC members, all working on same test bar odx has the Mologic and burnet Institute link which the others don’t.
I think it would be great. However Avacta do not currently have a test. I am in Avacta so not de ramping and would be delighted if it's true. It would make sense. Not sure that their test will be ready for another month or two but lets keep lining them up....
Hi Mikey :-)
No offense but you seem like a grade 1 twat, not sure how you cant see how a tie up with AVCT is hugely beneficial for ODX?
Its the stock market not a bloody football match
Why wouldn't we? AVCT have a 300 million investment with Cyvicta.
Why would AVCT go with BBI and Abingdon and not us when they need additional manufacturers. We'll get an RNS soon enough imo.
We already have 2 actual tests and 1 competing development test. Where do you think we have capacity for a phantom test that may never happen? Go and actually find out about Mologic and tell me they are not more likely to deliver a test, with $27m of investment from gates?
If D$gsy dollars is here thats it, ... its boom time $$$$
AS said today they will be going on Nasdaq in the future
Lovely. Https://www.yorkshirepost.co.uk/business/consumer/avacta-set-momentous-milestones-it-prepares-launch-covid-19-test-2985152 "Avacta plans to focus on the UK first and foremost in a bid to supply a cheap, simple, highly accurate test that can say whether people are infected with Covid-19. Some tests currently being used can provide false positives, leading people to self isolate when they are not actually infectious. It will then turn its attention to the US market. The firm is working with three UK manufacturers to make the tests: BBI Solutions, Abingdon Health and Omega Diagnostics. etc
Too much detail in the article not to be genuine, and plenty of quotes from the company, feel free to email Omega/PR for confirmation.
another line I like..."It will then turn its attention to the US market."
Aberdeenman
I doubt its genuine, ODX and AVCT both would released RNS first thing this morning
Likely they will now be rushing to get the MOU inked and signed, albeit with the usual caveats, no guarantee etc. etc.
However, how many UK companies can manufacture in sufficient quality and quantity??
Operation Moonshot will have a necessary bias towards UK companies with a second wave coming, as national supplies can be requisitioned by the domestic country, so foreign manufacture is inherently risky.
Even with caveats on an RNS, hold on tight folks!!
Aberdeenman
CK
Must confirm if AVCT are working with Omega
If we can manufacture for them, all good
Yes Clive... there will be an RNS from both... I assume later today or tomorrow...
Hardly speeding off course, just cruising nicely? Certainly no big spike following the Sky interview with Ck.
Clive - I agree - said that when it first came out. Intraday - simultaneous on both shares? Hopefully they are now running around getting it prepped so as to underpin the rise.
I refuse to get a 3rd speeding ticket!!!! That would put us on the bubble for a driving ban :-)